NCT07240649Not yet recruitingPhase 4
Emerging Indications for Hyperbaric Oxygen Treatment
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 26 Oct 2025
- Start date
- 1 Nov 2026
- Primary completion date
- 31 Dec 2035
- Lead sponsor
- Jay C. Buckey Jr.
- NCT number
- NCT07240649
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 1 Nov 2026 to the primary completion date, 31 Dec 2035
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)
Other
- Pregnant persons
Who the study is looking for
- Patients referred for HBOT with an emerging indication
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.